| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1378/CHEST.114.5_SUPPLEMENT.683S |
| P698 | PubMed publication ID | 9822071 |
| P50 | author | Ralph L Sacco | Q69142484 |
| P2093 | author name string | J D Easton | |
| G W Albers | |||
| P Teal | |||
| P433 | issue | 5 Suppl | |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 683S-698S | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Antithrombotic and thrombolytic therapy for ischemic stroke | |
| P478 | volume | 114 |
| Q42045752 | A rating system for prompt clinical diagnosis of ischemic stroke |
| Q73238461 | Acute Ischemic Stroke |
| Q51338278 | Aging has a complex effect on a rat model of ischemic stroke. |
| Q30306587 | Antiplatelet therapy in secondary stroke prevention |
| Q28195140 | Antithrombotic drug treatment of pediatric patients with ischemic stroke |
| Q74237119 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis |
| Q90325365 | Bone marrow-derived mesenchymal stem cell and simvastatin treatment leads to improved functional recovery and modified c-Fos expression levels in the brain following ischemic stroke |
| Q35113299 | Cardiovascular drug therapy in the elderly: theoretical and practical considerations |
| Q28192558 | Choices in medical management for prevention of acute ischemic stroke |
| Q34030132 | Clopidogrel: a review of its use in the prevention of atherothrombosis |
| Q36970318 | Current strategies for ischemic stroke prevention: role of multimodal combination therapies |
| Q39434130 | How well is the clinical importance of study results reported? An assessment of randomized controlled trials |
| Q47873194 | Need for Continued Use of Anticoagulants After Intracerebral Hemorrhage |
| Q48504563 | Pharmaceutical care for patients with ischemic stroke: improving the patients quality of life |
| Q52035287 | Racial differences in the prevalence of cardiac sources of embolism in subjects with unexplained stroke or transient ischemic attack evaluated by transesophageal echocardiography. |
| Q28195545 | Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage? |
| Q37148345 | Secondary prevention of atherothrombotic events after ischemic stroke |
| Q35799749 | Secondary stroke prevention: review of clinical trials |
| Q73209033 | Stroke prevention |
| Q36349902 | Targeting caspase-6 and caspase-8 to promote neuronal survival following ischemic stroke. |
| Q28165227 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial |
| Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
| Q35581150 | Treatments for stroke |
| Q34425229 | Use of 3-D magnetic resonance electrical impedance tomography in detecting human cerebral stroke: a simulation study |
| Q33640489 | Use of antithrombotic agents among U.S. stroke survivors, 2000-2006 |
| Q34776709 | Use of antithrombotic medications among elderly ischemic stroke patients |
| Q34000901 | Use of oral anticoagulants in older patients |
| Q44567973 | Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
Search more.